Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Use the pullback to buy pullback in this MedTech stock: JPMorgan
August 12, 2024 4:00 PM EDTJPMorgan analysts urged investors to capitalize on the recent pullback in one medtech company's shares.
The firm said in a note to clients Monday that Insulet's (NASDAQ: PODD) strong fundamentals and positive outlook mean they are buyers.
The analysts express frustration over the stock's decline following earnings last week, emphasizing that the drop is not reflective of the company's... More
Insulet Corporation (PODD) PT Lowered to $250 at BTIG
August 9, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on Insulet Corporation (NASDAQ: PODD) to $250.00 (from $270.00) while maintaining a Buy rating.
The analyst comments "Following its preannouncement in late July, Insulet reported Q2 revenue of $488.5M (+23% y/y rep and cc), a ~$27M beat on consensus at the time of the preannouncement. The beat came from all business segments and was attributed to strong O5 demand that drove sequential increases in new customer starts both in the... More
